A phase II study of M605106 for acne vulgaris

A phase II study to evaluate the efficacy and safety of M605106 short contact therapy in patients with acne vulgaris

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210011

Enrollment

240

Registered

2021-04-05

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris

Interventions

Apply an appropriate amount once a day and remove after a short time.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Acne vulgaris 12 to 49 years old

Exclusion criteria

Exclusion criteria: - Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study - Patients with a history of hypersensitivity to investigational drug ingredients - Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Percentage change in total lesion count after a certain period	—

Contacts

Public ContactClinical Trials Infomation -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026